Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference7 articles.
1. European Medicines Agency. Imraldi 40 mg solution for injection: summary of product characteristics. 2017.
http://www.ema.europa.eu/
. Accessed 4 July 2018.
2. Lee N, Kim M, Lee JAJ, et al. Biosimilarity between Humira and the biosimilar candidate SB5 in product quality [abstract no. 2495]. In: ACR/ARHP annual meeting; 2017.
3. European Medicines Agency. CHMP assessment report: imraldi (adalimumab biosimilar). 2017.
http://www.ema.europa.eu/
. Accessed 4 July 2018.
4. Shin D, Lee Y, Kim H, et al. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. J Clin Pharm Ther. 2017;42(6):672–8.
5. Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2018;70(1):40–8.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献